Jamie E. Chaft, MD, FASCO, on Neoadjuvant Osimertinib in Resectable EGFR-Mutated NSCLC

Posted: Friday, June 13, 2025

Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, discusses results of the NeoADAURA trial, which found that neoadjuvant osimertinib with or without chemotherapy improved major pathological response compared with chemotherapy alone in patients with resectable EGFR-mutated non–small cell lung cancer (NSCLC). 

---